Dual-antigen fusion protein vaccination induces protective immunity against Candida albicans infection in mice
Keran Jia Yanhao Zhang Mengyu Jiang Mengge Cui Jia Wang Jiajia Zhang Hua Wang Huihai Zhao Mengyan Li Quanming Zou Hao Zeng a National Engineering Research Center of Immunological Products,Department of Microbiology and Biochemical Pharmacy,College of Pharmacy,Army Medical University,Chongqing,Chinab Department of Clinical Laboratory,The 980th Hospital of PLA Joint Logistics Support Force (Bethune International Peace Hospital),Shijiazhuang,ChinaProfessor Quanming Zou Director of the National Engineering Research Center for Immunobiological Products at the Army Medical University,Professor of the second level,Doctoral Supervisor,member of the Pharmaceutical Discipline Review Group of the State Council's Academic Degrees Committee,and member of the National Pharmacopoeia Commission. He has long been engaged in innovative biopharmaceutical and vaccine research and development,as well as research on the mechanisms of chronic gastritis and gastric cancer caused by Helicobacter pylori. He took the lead in establishing an innovative team for vaccine research and development against severe infection pathogens in key national fields. He has presided over more than 30 major and key projects such as the National 863,973,Major New Drug Creation,and Support Plan. He is currently researching six original 1.1 class new drugs,has obtained three original new drug clinical trial approvals,and has received one 1.1 class new drug certificate and one drug registration approval. He has successfully developed the world's first H. pylori vaccine for the prevention of gastric diseases,won the second prize of the National Technological Invention,the first prize of the Chongqing Technological Invention,and the first prize of the Chongqing Natural Science. It was also rated as one of the "Top Ten Scientific and Technological Progresses of Chinese Universities" in 2015,"Top Ten Progresses in the Field of Life Sciences in China," and "Top Ten Progresses in the Field of Medical Biotechnology in China."Professor Hao Zeng Male,46 years old,Doctoral Supervisor,Postdoctoral Fellow at the University of Texas,Senior Visiting Scholar at the Harvard Medical Research Center. He currently serves as the Deputy Director of the National Engineering Research Center for Immunobiological Products. As the principal investigator,Professor Zeng has spent 13 years developing the "National Class I New Drug - Recombinant Pentavalent Staphylococcal Vaccine," which is currently the vaccine with the most protective antigens internationally and the only domestically developed vaccine in China that has been approved for Phase I,II,and III clinical trials and has started Phase III clinical trials. It was rated as a breakthrough project by the Ministry of Science and Technology in the "China Life Sciences and Biotechnology Development Report" and an important progress in the "National Action Plan to Combat Bacterial Resistance (2016-2020)," with 2 international invention patents and 20 national invention patents authorized.
DOI: https://doi.org/10.1080/21645515.2024.2406065
2024-09-28
Human Vaccines & Immunotherapeutics
Abstract:Candida albicans Is a leading cause of nosocomial bloodstream infections, particularly in immunocompromised patients. Current therapeutic strategies are insufficient, highlighting the need for effective vaccines. This study aimed to evaluate the efficacy of a dual-antigen fusion protein vaccine (AH) targeting the Als3 and Hyr1 proteins of C. albicans , using AlPO 4 as an adjuvant. The AH vaccine was constructed by fusing Als3 17-432 and Hyr1 25-350 proteins, and its immunogenicity was tested in BALB/c mice and New Zealand white rabbits. Mice received three intramuscular doses of the vaccine combined with AlPO 4 , followed by a lethal challenge with C. albicans SC5314. Survival rates, antibody responses, cytokine production, fungal burdens, and organ pathology were assessed. The vaccine's efficacy was also validated using rabbit serum. Mice vaccinated with the AH-AlPO 4 combination exhibited significantly higher antibody titers, particularly IgG and its subclasses, compared to controls ( p < .001). The survival rate of vaccinated mice was 80% post-infection, significantly higher than the control group ( p < .01). Vaccinated mice showed reduced fungal loads in the blood, kidneys, spleen, and liver ( p < .05). Increased levels of interferon gamma and interleukin (IL)-17A were observed, indicating robust T helper (Th) 1 and Th17 cell responses. Vaccination mitigated organ damage, with kidney and liver pathology scores significantly lower than those of unvaccinated mice ( p < .05). Rabbit serum with polyclonal antibodies demonstrated effective antifungal activity, confirming vaccine efficacy across species. The AH-AlPO 4 vaccine effectively induced strong immune responses, reduced fungal burden, and protected against organ pathology in C. albicans infections. These findings support further development of dual-antigen vaccine strategies. Candida , a fungus, is a major cause of bloodstream infections, especially in critical care settings. This study focused on developing a vaccine to protect against Candida infection. The vaccine targeted two key proteins, Als3p and Hyr1p, found on the surface of Candida , using a combination of these proteins. To create the vaccine, we used Als3p and Hyr1p to form a fusion protein called AH, and tested the vaccine on mice, administering it with different adjuvants (substances that enhance the immune response). The results showed that the AH vaccine, particularly when combined with the adjuvant AlPO 4 , induced a strong immune response in mice. This response included the production of specific antibodies and immune cells that are crucial for defending against Candida infections. Furthermore, mice receiving the AH-AlPO 4 vaccine showed significantly better survival rates and lower levels of fungal infection compared to the control group or another experimental group. The vaccine also protected vital organs, such as the kidneys and liver, from Candida -induced damage. Additionally, we used rabbit serum to validate the efficacy of the vaccine, providing cross-species confirmation of its effectiveness. The study demonstrated the potential of the AH vaccine in eliciting robust immune responses and reducing the severity of Candida albicans infections. In summary, this research introduces a promising AH vaccine, which shows effectiveness in protecting against Candida infections. The study's innovative approach and positive results contribute to the ongoing efforts to develop vaccines against fungal infections, addressing a critical healthcare challenge. Further research is needed to explore the vaccine's long-term effectiveness and safety for potential use in clinical settings.
immunology,biotechnology & applied microbiology